Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Gross Profit (2022 - 2025)

Historic Gross Profit for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $2.1 million.

  • Pharmaceuticals' Gross Profit fell 43.54% to $2.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.5 million, marking a year-over-year decrease of 2722.15%. This contributed to the annual value of $11.1 million for FY2024, which is 4441.45% down from last year.
  • According to the latest figures from Q2 2025, Pharmaceuticals' Gross Profit is $2.1 million, which was down 43.54% from $3.6 million recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Gross Profit registered a high of $11.0 million during Q4 2022, and its lowest value of $1.8 million during Q1 2024.
  • Over the past 4 years, Pharmaceuticals' median Gross Profit value was $5.0 million (recorded in 2022), while the average stood at $4.7 million.
  • Per our database at Business Quant, Pharmaceuticals' Gross Profit tumbled by 6456.98% in 2024 and then skyrocketed by 10038.76% in 2025.
  • Over the past 4 years, Pharmaceuticals' Gross Profit (Quarter) stood at $11.0 million in 2022, then crashed by 63.06% to $4.1 million in 2023, then crashed by 49.08% to $2.1 million in 2024, then fell by 0.44% to $2.1 million in 2025.
  • Its Gross Profit was $2.1 million in Q2 2025, compared to $3.6 million in Q1 2025 and $2.1 million in Q2 2024.